Relay Therapeutics Collaborates with Pfizer on Breast Cancer Trial

Relay Therapeutics, Inc. has just announced a clinical trial collaboration with Pfizer Inc. to evaluate atirmociclib, Pfizer's investigative selective-CDK4 inhibitor, in combination with Relay's own RLY-2608 and fulvestrant. The collaboration is aimed at patients with PI3Kα-mutated, HR+, HER2* metastatic breast cancer. The initial triplet combination of RLY-2608 + atirmociclib + fulvestrant is set to be evaluated, with the initiation planned by the end of 2024.

RLY-2608, Relay Therapeutics' lead program, is focused on discovering and developing mutant selective inhibitors of PI3Kα, which is the most frequently mutated kinase in all cancers, with oncogenic mutations detected in about 14% of patients with solid tumors. The potential patient population for RLY-2608 in the United States is estimated to be over 250,000 per year, making it one of the largest patient populations for a precision oncology medicine.

The unique aspect of RLY-2608 is that it is the first known allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor, designed to overcome the limitations of traditional orthosteric inhibitors. The development of RLY-2608 was enabled by Relay Therapeutics' Dynamo™ platform, which facilitated the discovery and design of the inhibitor.

Under the terms of the agreement, Pfizer will provide atirmociclib for use in the study, and Relay will be responsible for conducting the study. This collaboration demonstrates Relay Therapeutics' commitment to leveraging leading-edge computational and experimental technologies to transform the drug discovery process and address the evolving landscape of breast cancer treatment.

This collaboration and the potential initiation of the triplet combination study by the end of 2024 mark significant advancements in the field of precision oncology and the development of targeted therapies for breast cancer patients with specific genetic mutations. Following these announcements, the company's shares moved -0.3%, and are now trading at a price of $7.32. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.